EAM
PBYI icon

Erste Asset Management’s Puma Biotechnology PBYI Stock Holding History

Erste Asset Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-12,200
Closed -$261K – 434
2018
Q4 		$261K Buy
+12,200
New +$366K 0.02% 349

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Erste Asset Management's PBYI Position: Q1 2019 in Review

Erste Asset Management sold out of Puma Biotechnology (PBYI) in Q1 2019, closing a stake of 12,200 shares — an estimated $261K sold.

Erste Asset Management first reported a position in PBYI in Q4 2018 and held it in 1 quarter. The position peaked at $261K in Q4 2018. 158 funds tracked by Wall St. Rank hold PBYI as of Q1 2019.

  • Erste Asset Management reported no remaining Puma Biotechnology position as of Q1 2019 after selling out during the quarter.
  • Erste Asset Management sold 12,200 Puma Biotechnology shares in Q1 2019, an estimated $261K.
  • Erste Asset Management first reported a position in Puma Biotechnology in Q4 2018 and held it in 1 quarter.
  • Erste Asset Management's Puma Biotechnology position peaked at $261K in Q4 2018.
  • 158 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2019.

Based on Erste Asset Management's 13F filing for Q1 2019, filed 22 Nov 2024.